Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bispecific Antibodies in the Treatment of Hematologic Malignancies.
Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, Gill S. Duell J, et al. Among authors: alekar s. Clin Pharmacol Ther. 2019 Oct;106(4):781-791. doi: 10.1002/cpt.1396. Epub 2019 Mar 29. Clin Pharmacol Ther. 2019. PMID: 30770546 Free PMC article. Review.
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Brüggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC. Topp MS, et al. Among authors: alekar s. J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10. J Clin Oncol. 2014. PMID: 25385737 Clinical Trial.
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.
Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, Stelljes M, Bargou RC, Goebeler M, Wessiepe D, Degenhard E, Gökbuget N, Klinger M. Zugmaier G, et al. Among authors: alekar s. Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64. Blood Cancer J. 2014. PMID: 25192414 Free PMC article. Clinical Trial. No abstract available.
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Maitland ML, Sachdev JC, Sharma MR, Moreno V, Boni V, Kummar S, Stringer-Reasor E, Lakhani N, Moreau AR, Xuan D, Li R, Powell EL, Jackson-Fisher A, Bowers M, Alekar S, Xin X, Tolcher AW, Calvo E. Maitland ML, et al. Among authors: alekar s. Clin Cancer Res. 2021 Aug 15;27(16):4511-4520. doi: 10.1158/1078-0432.CCR-20-3757. Epub 2021 Jun 3. Clin Cancer Res. 2021. PMID: 34083232 Free PMC article.
Serum magnesium in tetanus.
Natu MN, Sapatnekar SM, Alekar SV. Natu MN, et al. Among authors: alekar sv. Indian J Med Sci. 1980 Feb;34(2):24-6. Indian J Med Sci. 1980. PMID: 7419265 No abstract available.